Bezwoda published the first randomised controlled trial of high-dose versus conventional-dose chemotherapy as first-line treatment for metastatic breast cancer in October 1995 [REF].
The Philadelphia Intergroup Study (PBT-1) was the largest randomized trial of HDC versus conventional dose chemotherapy in responding metastatic breast cancer [REF].